RSS Worldwide Bio News

  • Endometriosis Self-care: Skin Care Matters
    This post was originally published on this site Skin care may not be the first thing you think of when discussing endometriosis. But the state of my skin is a recurrent theme in my life. As an adult acne sufferer, I’ve lost count of the number times I’ve been asked about, even mocked, over my […]
  • Ozanimod Results Promising in Crohn’s Disease, Ulcerative Colitis, Phase 2 Trial Data Show
    This post was originally published on this site Celgene recently presented positive data from two Phase 2 studies — the STEPSTONE and TOUCHSTONE studies — for the company’s investigational compound ozanimod (RPC-1063) as a therapy for Crohn’s disease and ulcerative colitis at the World Congress of Gastroenterology at ACG2017  in Orlando, Florida, Oct. 13-18. “The new STEPSTONE findings further […]
  • FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients
    This post was originally published on this site The U.S. Food and Drug Administration (FDA) will review AstraZeneca and Merck‘s application seeking the extension of Lynparza (olaparib) tablets for the treatment of HER-negative metastatic breast cancer patients whose tumors carry a germline mutation in the BRCA gene. The supplemental new drug application, meant for patients […]
  • Arena Pharmaceutical’s Ralinepag Shows Promise in Treating PAH in Phase 2 Clinical Trial
    This post was originally published on this site Patients with pulmonary arterial hypertension (PAH) taking Arena Pharmaceuticals‘ next-generation therapy Ralinepag (APD811) showed significant improvements in blood flow and exercise capacity in a Phase 2 clinical trial. Results of the study (NCT02279160) will be presented at the American College of Chest Physicians 2017 (CHEST) Annual Meeting, to be held […]
  • Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show
    This post was originally published on this site Trovagene’s enzyme inhibitor PCM-075 increases the punch of the prostate cancer therapy Zytiga (abiraterone), preclinical-trial studies show. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. It stymies a protein called PLK1, whose levels are particularly high in cancer cells. Studies have shown that inhibiting PLK1 triggers the death of tumor cells. […]
  • Latest Clinical Data Presented on GS010 for Mitochondria Disease of the Eyes
    This post was originally published on this site The latest clinical data continue to demonstrate the therapeutic potential of GenSight Biologics‘ lead candidate GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease. These data further support ongoing Phase 3 clinical trials. Trial data were presented at the 25th annual congress […]
  • Ovarian Cancer Gene Therapy Specialist Is One of Three Researchers Sharing $1.3 Million in Grants
    This post was originally published on this site Three American scientists have received $1.3 million from the Alliance for Cancer Gene Therapy to investigate whether immunotherapy and gene therapy can combat three of the most life-threatening forms of cancer: ovarian, brain and bone cancer. The three are Drs. Daniel Powell Jr. of the University of Pennsylvania’s Perelman […]
  • Type of Multiple Myeloma May Affect Responses to Darzalex, Study Finds
    This post was originally published on this site A new study reports that the specific type of multiple myeloma (MM) may affect how long the drug Darzalex (daratumumab) remains in circulation, affecting its effectiveness for the treatment and management of the disease. Results from the study, “Influence of Disease and Patient Characteristics on Daratumumab Exposure […]
  • Amgen and CytomX Therapeutics Announce Partnership for Immuno-Oncology Research
    This post was originally published on this site Amgen and CytomX Therapeutics have announced a partnership to jointly develop a new technology that uses antibodies to direct T-cells, a type of immune cell, to kill tumor cells. The approach, known as Probody T-cell engaging bispecific antibodies, enables access to targets considered inaccessible to conventional antibodies due […]
  • LFA Appoints New Chair of Medical-Scientific Advisory Council
    This post was originally published on this site Karen H. Costenbader, MD, is the new chairwoman of the medical-scientific advisory council of the Lupus Foundation of America (LFA). Chairman of the LFA’s national board of directors, Conrad Gehrmann, announced the appointment earlier this week. Costenbader will lead the multi-disciplinary group of lupus experts to address unmet needs […]